Maturitas

Menopause -- a modern perspective from a controversial history
pp. 73-82(10)
Author: Utian W.H.

Sexuality, hormones and the menopausal transition
pp. 83-93(11)
Authors: Dennerstein L.; Dudley E.C.; Hopper J.L.; Burger H.

Comparison of the local tolerability and adhesion of a new matrix system (Menorest(R)) for estradiol delivery with an established transdermal membrane system (Estraderm TTS(R))
pp. 95-101(7)
Authors: Erianne J.A.; Winter L.

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses
pp. 103-111(9)
Authors: Antoniou G.; Kalogirou D.; Karakitsos P.; Antoniou D.; Kalogirou O.; Giannikos L.

Effects of hormone replacement therapy on serum amyloid P component in postmenopausal women
pp. 113-119(7)
Authors: Hashimoto S.; Katou M.; Dong Y.; Murakami K.; Terada S.; Inoue M.

The effect of hormone replacement therapy on vitamin E status in postmenopausal women
pp. 121-124(4)
Authors: Yichuan W.; Doyle M.C.T.; Harrison R.F.; Feely J.

Cardiovascular risk factors during sequentially combined 17 oestradiol and dydrogesterone (Femoston(R)); results from a one-year study in postmenopausal women
pp. 125-132(8)
Authors: Gelfand M.; Fugere P.; Bissonnette F.

Difference of LH and FSH secretory characteristics and degree of concordance between postmenopausal and aging women
pp. 133-138(6)
Authors: Genazzani A.D.; Petraglia F.; Sgarbi L.; Montanini V.; Hartmann B.; Surico N.; Biolcati A.; Volpe A.; Genazzani A.R.

HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women
pp. 139-149(11)
Authors: Heikkinen J.; Kyllonen E.; Kurttila-Matero E.; Wilen-Rosenqvist G.; Lankinen K.S.; Rita H.; Vaananen H.K.

The confirmation of a biochemical marker for women's hormonal migraine: the depo-estradiol challenge test
pp. 151-151(1)
Authors: Lichten E.M.; Lichten J.B.; Whitty A.; Pieper D.

Impact of a 12-month exercise program on the physical and psychological health of osteopenic women
pp. 151-152(2)
Authors: Bravo G.; Gauthier P.; Roy P.-M.; Payette H.; Gaulin P.; Harvey M.; Peloquin L.; Dubois M.-F.

Mortality following fractures in older women: the study of osteoporotic fractures
pp. 152-152(1)
Authors: Browner W.S.; Pressman A.R.; Nevitt M.C.; Cummings S.R.

Confirmation of early menopause in fragile X carriers
pp. 152-152(1)
Authors: Partington M.W.; Moore D.Y.; Turner G.M.

Change of serum amyloid P component concentrations in women
pp. 153-153(1)
Author: Katou M.

Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
pp. 153-153(1)
Authors: Grodstein F.; Stampfer M.J.; Manson J.E.; Colditz G.A.; Willett W.C.; Rosner B.; Speizer F.E.; Hennekens C.H.

Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis
pp. 153-154(2)
Authors: Jonas H.A.; Kronmal R.A.; Psaty B.M.; Manolio T.A.; Meilahn E.N.; Tell G.S.; Tracy R.P.; Robbins J.A.; Anton-Culver H.

Risk factors for osteoporotic fractures in elderly men
pp. 154-154(1)
Authors: Nguyen T.V.; Eisman J.A.; Kelly P.J.; Sambrook P.N.

Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture. A 15-year follow-up study
pp. 154-155(2)
Authors: Riis B.J.; Hansen M.A.; Jensen A.M.; Overgaard K.; Christiansen C.

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study
pp. 155-155(1)
Authors: Walsh L.J.; Wong C.A.; Pringle M.; Tattersfield A.E.

Hormonal support of lacrimal function, primary lacrimal deficiency, autoimmunity, and peripheral tolerance in the lacrimal gland
pp. 155-156(2)
Authors: Mircheff A.K.; Warren D.W.; Wood R.L.